Scottish Biopharmaceutical Company MGB Biopharma Receives £2.78m Grant Award For Phase IIa Clinical Trial
MGB Biopharma – FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)
MGB Biopharma Granted Qualified Infectious Disease Product (QIPD) Designation by U.S. FDA for the Treatment of Clostridium difficile-associated Diarrhoea (CDAD) for MGB-BP-3
